Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;26(11):4996-5004.
doi: 10.1111/dom.15912. Epub 2024 Sep 16.

Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies

Anton Pottegård  1 , Jacob H Andersen  1 , Jens Søndergaard  2 , Lotte Rasmussen  1 , Helene Kildegaard  1 , Tina Vilsbøll  3   4 , Reimar W Thomsen  5
Affiliations

Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies

Anton Pottegård et al. Diabetes Obes Metab. 2024 Nov.

Abstract

Aim: To analyse patterns of glucose-lowering therapies among people with type 2 diabetes (T2D) in Denmark from 2016 to 2023.

Materials and methods: We examined time trends in the clinical profiles of people with T2D who initiated different glucose-lowering therapy classes for the first time. We furthermore investigated individual-level treatment trajectories following first-ever glucose-lowering therapy in people with or without cardiorenal disease. The study utilized data from the nationwide Danish health registries and included all individuals who filled a first-ever prescription for metformin, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium-glucose co-transporter-2 inhibitors (SGLT-2is) or insulin, excluding those without HbA1c-confirmed T2D or probable type 1 diabetes.

Results: We included 260 393 individuals initiating a new glucose-lowering therapy class from 2016 to 2023, during which there were 6- and 3-fold increases in initiators of GLP-1RAs and SGLT-2is, respectively. The median HbA1c level at treatment initiation with GLP-1RAs or SGLT-2is decreased, from 67-68 mmol/mol in 2016-2017 to 57-58 mmol/mol in 2022-2023. Among individuals who initiated metformin as first-line therapy, the proportion who started additional glucose-lowering therapy within 2 years increased from 25% in 2016 to 40% in 2021. Among the 38% of individuals who had established cardiorenal disease when they initiated first-ever glucose-lowering therapy in 2020, 22% used SGLT-2is and 18% GLP-1RAs after 2.5 years, compared with 17% and 21% among initiators without cardiorenal disease, respectively.

Conclusions: Our study documents a trend towards earlier T2D treatment intensification and an increase in the use of GLP-1RAs and SGLT-2is in Denmark. However, optimal T2D treatment is still not received by most individuals with early T2D and established cardiorenal disease.

Keywords: antidiabetic drug; database research; pharmaco‐epidemiology; type 2 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022;400:1803‐1820.
    1. Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country‐level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
    1. Gaede P, Lund‐Andersen H, Parving H‐H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580‐591.
    1. American Diabetes Association Professional Practice Committee. Summary of revisions: standards of care in diabetes‐2024. Diabetes Care. 2024;47:S5‐S10.
    1. Davies MJ, Aroda VR, Collins BS, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;2022(65):1925‐1966.

Publication types

MeSH terms

LinkOut - more resources